Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Pre and postoperative objective assessment of quality of vision in patients undergoing YAG vitreolysis using wavefront aberrometry

Poster Details

First Author: I.Singh USA

Co Author(s):                        

Abstract Details


To objectively analyze the impact on quality of vision in patients undergoing YAG vitreolysis for the treatment of symptomatic floaters.


The Eye Centers of Racine and Kenosha, Wisconsin, USA


In this retrospective case series, 36 eyes of 24 symptomatic patients who complained of reduced daily functioning due to floaters were preoperatively diagnosed with amorphous floaters located near the central visual axis. All patients underwent YAG vitreolysis using the Ultra Q Reflex YAG laser (Ellex, Adelaide, Australia). Preoperatively and at postoperative week 6, patients were scanned prior to dilation using the iTrace wavefront aberrometer (TRACEY Technologies, Texas, USA) to objectively assess quality of vision. Pre- and postoperative scans were reviewed and compared for changes in higher order aberrations (HOAs), modular transfer function (MTF) curves, and dysfunctional lens index (DLI).


Wavefront aberrometry revealed reduced HOAs, MTF curves, and or improved DLI in 33/36 eyes. The mean reduction of HOA was 53%. The greatest reduction was observed in trefoil and then coma (mean total HOA pre-op: 0.24, mean post-op: 0.08). MTF analysis showed a 50% increase in the mean area under the curve postoperatively (mean preop: 0.273, mean postop: 4.10). The mean DLI improved from 5.2 to 8.3. There were no adverse events reported and Snellen visual acuity did not change during postoperative exams. Pupil size was similar in all scans.


In this pilot study in which quality of vision was objectively evaluated via wavefront aberrometry, the findings indicate that YAG vitreolysis can potentially improve quality of vision in patients with symptomatic floaters. This might provide more rationale to address floaters in patient who are symptomatic. A larger study is currently underway to corroborate and expand upon these findings.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to Poster listing